Kentaro Iwaki

Dr. Kentaro Iwaki

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in HPB
Verified
Journal Article
Closed access
TITakamichi Ishii
Takamichi Ishii
KIKentaro Iwaki
Kentaro Iwaki
ANAkiyoshi Nakakura
Akiyoshi Nakakura
TYTomoaki Yoh
Tomoaki Yoh
YUYoichiro Uchida
Yoichiro Uchida
EHEtsuro Hatano
Etsuro Hatano

16 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KIKentaro Iwaki
Kentaro Iwaki
SKSatoshi Kaihara
Satoshi Kaihara
TKTatsuya Koyama
Tatsuya Koyama
KNKai Nakao
Kai Nakao
SMShotaro Matsuda
Shotaro Matsuda
KUKenji Uryuhara
Kenji Uryuhara
Local recurrence after colorectal liver metastasis (CRLM) resection severely affects survival; however, the required surgical margin width remains controversial. This study investigated the impact of KRAS status on surgical margin width and local recurrence rate (LRR) post-CRLM resection. Overall, 146 resected CRLMs with KRAS status (wild-type KRAS (wtKRAS): 98, KRAS mutant (mKRAS): 48) were included. The LRR for each group, R1 (margin positive) and R0 (margin negative), was analyzed by KRAS status. R0 was further stratified into Ra (margin ≥ 5 mm) and Rb (margin < 5 mm). Patients with local recurrence had significantly worse 5-year overall survival than those without local recurrence (p = 0.0036). The mKRAS LRR was significantly higher than wtKRAS LRR (p = 0.0145). R1 resection resulted in significantly higher LRRs than R0 resection for both wtKRAS and mKRAS (p = 0.0068 and p = 0.0204, respectively), and while no significant difference was observed in the Ra and Rb LRR with wtKRAS, the Rb LRR with mKRAS (33.3%) was significantly higher than Ra LRR (5.9%) (p = 0.0289). Thus, R0 resection is sufficient for CRLM with wtKRAS; however, CRLM with mKRAS requires resection with a margin of at least 5 mm to prevent local recurrence.

6 September 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
KIKentaro Iwaki
Kentaro Iwaki
SKSatoshi Kaihara
Satoshi Kaihara
RKRyosuke Kita
Ryosuke Kita
KKKoji Kitamura
Koji Kitamura
HHHiroki Hashida
Hiroki Hashida
KUKenji Uryuhara
Kenji Uryuhara
Preoperative evaluation of future remnant liver reserves is important for safe hepatectomy. If the remnant is small, preoperative portal vein embolization (PVE) is useful. Liver volume analysis has been the primary method of preoperative evaluation, although functional examination may be more accurate. We have used the functional evaluation liver using the indocyanine green plasma clearance rate (KICG) and 99mTc-galactosyl human serum albumin single-photon emission computed tomography (99mTc-GSA SPECT) for safe hepatectomy. To analyze the safety of our institution’s system for evaluating the remnant liver reserve. We retrospectively reviewed the records of 23 patients who underwent preo perative PVE. Two types of remnant liver KICG were defined as follows: Anatomical volume remnant KICG (a-rem-KICG), determined as the remnant liver anatomical volume rate × KICG; and functional volume remnant KICG (f-rem-KICG), determined as the remnant liver functional volume rate based on 99mTc-GSA SPECT × KICG. If either of the remnant liver KICGs were > 0.05, a hepatectomy was performed. Perioperative factors were analyzed. We defined the marginal group as patients with a-rem-KICG of < 0.05 and a f-rem-KICG of > 0.05 and compared the postoperative outcomes between the marginal and not marginal (both a-rem-KICG and f-rem-KICG > 0.05) groups. All 23 patients underwent planned hepatectomies. Right hepatectomy, right trisectionectomy and left trisectionectomy were in 16, 6 and 1 cases, respectively. The mean of blood loss and operative time were 576 mL and 474 min, respectively. The increased amount of f-rem-KICG was significantly larger than that of a-rem-KICG after PVE (0.034 vs 0.012, P = 0.0273). The not marginal and marginal groups had 17 (73.9%) and 6 (26.1%) patients, respectively. The complications of Clavian-Dindo classification grade II or higher and post-hepatectomy liver failure were observed in six (26.1%) and one (grade A, 4.3%) patient, respectively. The 90-d mortality was zero. The marginal group had no significant difference in postoperative outcomes (prothrombin time/international normalised ratio, total bilirubin, complication, post-hepatectomy liver failure, hospital stay, 90-d, and mortality) compared with the not-marginal group. Functional evaluation of the remnant liver enabled safe hepatectomy and may extend the indication for hepatectomy after PVE treatment.

6 March 2021 in Surgery Today
Verified
Journal Article
Closed access
PDF file
KIKentaro Iwaki
Kentaro Iwaki
SKSatoshi Kaihara
Satoshi Kaihara
KKKoji Kitamura
Koji Kitamura
KUKenji Uryuhara
Kenji Uryuhara

13 June 2025 in Tissue Engineering Part A
Verified
Journal Article
Closed access
HHHiroshi Horie
Hiroshi Horie
YOYu Oshima
Yu Oshima
KFKen Fukumitsu
Ken Fukumitsu
KIKentaro Iwaki
Kentaro Iwaki
FMFumiaki Munekage
Fumiaki Munekage
EHEtsuro Hatano
Etsuro Hatano
A bioengineered liver has the potential to save patients with end-stage liver disease, and a three-dimensional decellularized scaffold is a promising approach for practical use. The main challenge in bioengineered liver transplantation is thrombogenicity during blood perfusion. We aimed to apply a novel antithrombotic polymer to revascularize liver scaffolds and evaluate the thrombogenicity and biosafety of the polymer-treated scaffolds. A biomimetic polymer, 2-metacryloyloxyethyl phosphorylcholine (MPC) was prepared for modification of the extracellular matrix in liver scaffolds. The polymer was injected into the rat liver scaffolds’ portal vein and could extensively react to the vessel walls. In an ex vivo blood perfusion experiment, we demonstrated significantly less platelet deposition in the polymer-treated scaffolds than nontreated or re-endothelialized scaffolds with human umbilical vein endothelial cells. In the heterotopic transplantation model, liver volume was better maintained in the polymer-treated groups, and platelet deposition was suppressed in these groups. Additionally, the polymer-treated liver scaffolds maintained the metabolic function of the recellularized rat primary hepatocytes during perfusion culture. The MPC polymer treatment efficiently suppressed thrombus formation during blood perfusion in liver scaffolds and maintained the function of recellularized hepatocytes. Revascularizing liver scaffolds using this polymer is a promising approach for bioengineered liver transplantation. Impact Statement: Thrombogenicity is one of the most critical challenges in bioengineered liver transplantation using decellularization techniques. We developed a new strategy for antithrombotic revascularization of bioengineered livers with a biomimetic 2-metacryloyloxyethyl phosphorylcholine polymer to the extracellular matrix. The polymer treatment was demonstrated to be safe for recellularized hepatocytes. This novel approach should be a key for clinical application of bioengineered liver transplantation.

20 November 2023 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
TITakamichi Ishii
Takamichi Ishii
KIKentaro Iwaki
Kentaro Iwaki
ANAkiyoshi Nakakura
Akiyoshi Nakakura
YUYoichiro Uchida
Yoichiro Uchida
TITakashi Ito
Takashi Ito
EHEtsuro Hatano
Etsuro Hatano
Background/Purpose: The anterior approach (AA) in liver resection has proven more effective with regard to short‐term outcomes than the conventional approach (CA). However, its superiority over the CA concerning long‐term outcomes remains unclear. This meta‐analysis compared the short‐ and long‐term outcomes of the AA and CA.Methods: Databases, including MEDLINE, Web of Science, and Cochrane Central Register of Controlled Trials, were searched to identify studies comparing the AA and CA for hepatocellular carcinoma (HCC) liver resection. The primary outcomes were the in‐hospital mortality, in‐hospital morbidity, disease‐free survival (DFS), and overall survival (OS). Secondary outcomes were operative time, blood loss, blood transfusion, R0 rate, and length of hospital stay.Results: Ten studies involving 1369 patients were included (AA, n = 595; CA, n = 774). Despite no significant differences in the in‐hospital mortality or morbidity, the AA demonstrated a superior DFS (hazard ratio [HR], 0.63; 95% confidence interval [CI]: 0.51–0.77) and OS (HR, 0.56; 95% CI: 0.48–0.65) and was associated with a longer operative time, less blood loss, and less transfusion than the CA. No marked differences in other outcomes were noted.Conclusions: The AA for HCC liver resection helped reduce blood loss and need for transfusion, improving the DFS and OS.